Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Detailed price information for Apogee Therapeutics Inc (APGE-Q) from The Globe and Mail including charting and trades.

Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

Incyte has delivered a pair of pivotal wins for an oral JAK inhibitor in an inflammatory skin condition. But with the placebo ...

Multiple risk factors were associated with denials and longer wait times for biologic treatment in moderate to severe asthma, ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc.

Gov. Wes Moore made lowering drug costs a key campaign promise, making advocates of the law confident that their greatest ...

The final appraisal document for Dupixent (dupilumab ... for people aged over 12 with severe asthma characterised by type 2 inflammation and uncontrolled using standard drugs.

Dupixent is generally dosed every two or four ... as a monotherapy in adults with moderate-to-severe AD (COAST 1 and 2), a study looking at the drug in combination with background topical ...

Only show cars that can be delivered to me. Please enter your postal code in order to show cars that can be delivered to you.

Dupixent Market Report 2025 The Business Research Company's Global Dupixent Market Outlook 2025-2034: Growth Drivers, Share, And Trends ...